Table 4.

The association of DAAs vs IFN-induced SVR with HCV recurrence by meta-regression analysis

Variables	Univariate analysis			Multivariate analysis
	RR	95% CI	P value	aRR	95% CI	P value
Low-risk HCV mono-infected population
Treatment
IFN	1.0000			1.0000
DAAs	0.9915	0.9679,1.0157	0.4888	0.9893	0.9520,1.0280	0.5813
Average follow-up, years	0.9950	0.9900,1.0002	0.0586	0.9946	0.9885,1.0009	0.0909
Average age, year	0.9990	0.9973,1.0006	0.2293	0.9989	0.9967,1.0012	0.3559
High-risk HCV mono-infected population
Treatment
IFN	1.0000			1.0000
DAAs	1.0107	0.9371,1.0900	0.7834	0.9924	0.9205,1.0700	0.8439
Average follow-up, years	0.9800	0.9513,1.0096	0.1844	0.9572	0.9256,0.9990	0.0108
Average age, year	0.9971	0.9935,1.0006	0.1059	0.9937	0.9892,0.9982	0.0063
HIV/HCV coinfected population
Treatment
IFN	1.0000			1.0000
DAAs	0.9921	0.8255,1.1924	0.9328	0.8784	0.7354,1.0493	0.1528
Average follow-up, years	0.9227	0.8728,0.9755	0.0046	0.8761	0.8419,0.9117	<0.0001
Average age, year	0.9957	0.9839,1.0075	0.4751	0.9948	0.9854,1.0044	0.3740

Abbreviations: RR, relative risk; aRR, adjusted relative risk.